Navigating Global Access, Regulatory Harmonization, and Future Directions in CAR-T Cell Therapy: Insights from a Global Panel Discussion

Navigating Global Access, Regulatory Harmonization, and Future Directions in CAR-T Cell Therapy: Insights from a Global Panel Discussion

2025.11.18
The Cellular Therapy and Immunotherapy Conference 2025 was successfully held in Hangzhou, China, from November 13-16, 2025. The conference brought together a distinguished gathering of the world's leading researchers, clinicians, and industry pioneers to share groundbreaking advancements and foster collaboration in the rapidly advancing fields of cellular and immune-based treatments. The morning's agenda offered a comprehensive survey of the global landscape, featuring in-depth presentations on the evolution of CAR-T cell therapies in China, Europe, and Japan. The discussions also addressed critical challenges in navigating regulatory frameworks, ensuring patient access, and maintaining affordability for cell and gene therapies across diverse regions, including Asia, Latin America, and other resource-limited settings. Culminating these insightful sessions was a dynamic Panel Discussion. This concluding segment provided a vital forum for the session's international experts to synthesize the diverse perspectives shared, engage in a robust dialogue on overcoming current obstacles, and collaboratively envision the future trajectory of immunotherapy and cell therapy on a global scale. The discussion underscored a collective commitment to advancing these transformative treatments from the laboratory to patients in need worldwide.
FACO China–Japan Expert Dialogue | Professors Jin Li, Xiaotian Zhang, and Koji Kono Discuss Precision Treatment Advances in HER2-Positive Gastric Cancer

FACO China–Japan Expert Dialogue | Professors Jin Li, Xiaotian Zhang, and Koji Kono Discuss Precision Treatment Advances in HER2-Positive Gastric Cancer

2025.11.13
China, Japan, and other Asian countries have some of the highest rates of gastric cancer worldwide. In China, the majority of patients are still diagnosed at an advanced stage, having already lost the opportunity for curative surgery. Effective systemic therapy is therefore essential for improving survival. In recent years, innovative drugs represented by antibody–drug conjugates (ADCs)—such as the HER2-targeted ADC trastuzumab deruxtecan (T-DXd)—have achieved major breakthroughs in pivotal clinical studies including DESTINY-Gastric04. These advances are expected to gradually transform the treatment landscape starting from later lines of therapy. Asian clinical researchers have played an important role in these studies, contributing insights that are redefining clinical practice.
Professors Michael R. Bishop and Edmund K. Waller Visit Peking University Institute of Hematology:Sino–U.S. Experts Discuss the Future of Cell Therapy

Professors Michael R. Bishop and Edmund K. Waller Visit Peking University Institute of Hematology:Sino–U.S. Experts Discuss the Future of Cell Therapy

2025.11.06
On November 2, 2025, world-renowned hematology experts Professor Michael R. Bishop, Director of the Cell Therapy Center at the University of Chicago, and Professor Edmund K. Waller, the Rein Saral Distinguished Chair at Emory University, visited the Peking University Institute of Hematology for an academic exchange.
ESMO China Voice | Prof. Jiayu Wang: MAIC Analysis Highlights the Potential of Bireociclib as a Second-Line Therapy for HR+/HER2– Advanced Breast Cancer, Offering a New Treatment Option for Patients 

ESMO China Voice | Prof. Jiayu Wang: MAIC Analysis Highlights the Potential of Bireociclib as a Second-Line Therapy for HR+/HER2– Advanced Breast Cancer, Offering a New Treatment Option for Patients 

2025.11.05
In the second-line treatment of hormone receptor–positive, HER2-negative (HR+/HER2–) advanced breast cancer, CDK4/6 inhibitors combined with fulvestrant have become the standard of care. However, variations in efficacy and safety profiles among different inhibitors remain an important clinical consideration.